Related Experiment Video
Updated: Aug 15, 2026
07:05
Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
Published on: January 3, 2017
Application of PET in dementia disorders
1Department of Clinical Neuroscience and Family Medicine, Karolinska Institute, Huddinge University Hospital, Sweden.
Acta Neurologica Scandinavica. Supplementum
|January 1, 1996
Summary
Positron emission tomography (PET) aids in understanding dementia by revealing brain changes. This functional imaging technique shows promise for early dementia detection and monitoring treatment effectiveness.
Area of Science:
- Neuroimaging
- Neurology
- Medical Diagnostics
Background:
- Positron emission tomography (PET) is crucial for assessing brain changes in dementia.
- PET provides physiological correlates vital for dementia diagnosis, management, and research.
- A key question is PET's capability for early or preclinical dementia detection.
Purpose of the Study:
- To explore the role of PET in understanding functional and structural brain changes in dementia.
- To investigate the potential of PET for early and preclinical detection of dementia.
- To examine the utility of PET in monitoring treatment effects for dementia disorders.
Main Methods:
- Utilizing longitudinal PET studies, particularly in Alzheimer's families with chromosomal aberrations.
- Analyzing cerebral blood flow and glucose metabolism patterns in dementia patients.
- Applying neuroreceptor studies and monitoring drug treatment effects.
Main Results:
- Impairment in cerebral blood flow and glucose metabolism is a hallmark of Alzheimer's disease.
- Distinct patterns of metabolic changes differentiate Alzheimer's from other dementias.
- PET findings correlate with observed neuropsychological impairments.
Conclusions:
- PET is a valuable tool for understanding dementia pathophysiology and progression.
- PET shows potential for early diagnosis and monitoring of dementia.
- Further application of neuroreceptor PET and treatment monitoring is recommended.
Related Concept Videos
01:29Positron Emission Tomography
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...